Delimiting MOGAD as a disease entity using translational imaging
The first formal consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) were recently proposed. Yet, the distinction of MOGAD-defining characteristics from characteristics of its important differential diagnoses such as multiple sclerosis (MS) and a...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-12-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2023.1216477/full |
| _version_ | 1797268427935580160 |
|---|---|
| author | Frederike Cosima Oertel Frederike Cosima Oertel Frederike Cosima Oertel Maria Hastermann Maria Hastermann Friedemann Paul Friedemann Paul Friedemann Paul |
| author_facet | Frederike Cosima Oertel Frederike Cosima Oertel Frederike Cosima Oertel Maria Hastermann Maria Hastermann Friedemann Paul Friedemann Paul Friedemann Paul |
| author_sort | Frederike Cosima Oertel |
| collection | DOAJ |
| description | The first formal consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) were recently proposed. Yet, the distinction of MOGAD-defining characteristics from characteristics of its important differential diagnoses such as multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (NMOSD) is still obstructed. In preclinical research, MOG antibody-based animal models were used for decades to derive knowledge about MS. In clinical research, people with MOGAD have been combined into cohorts with other diagnoses. Thus, it remains unclear to which extent the generated knowledge is specifically applicable to MOGAD. Translational research can contribute to identifying MOGAD characteristic features by establishing imaging methods and outcome parameters on proven pathophysiological grounds. This article reviews suitable animal models for translational MOGAD research and the current state and prospect of translational imaging in MOGAD. |
| first_indexed | 2024-03-08T11:38:17Z |
| format | Article |
| id | doaj.art-676e278f17474b62bc121a6d3b26c061 |
| institution | Directory Open Access Journal |
| issn | 1664-2295 |
| language | English |
| last_indexed | 2024-04-25T01:32:19Z |
| publishDate | 2023-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj.art-676e278f17474b62bc121a6d3b26c0612024-03-08T11:12:14ZengFrontiers Media S.A.Frontiers in Neurology1664-22952023-12-011410.3389/fneur.2023.12164771216477Delimiting MOGAD as a disease entity using translational imagingFrederike Cosima Oertel0Frederike Cosima Oertel1Frederike Cosima Oertel2Maria Hastermann3Maria Hastermann4Friedemann Paul5Friedemann Paul6Friedemann Paul7Experimental and Clinical Research Center, Max-Delbrück-Centrum für Molekulare Medizin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyNeuroscience Clinical Research Center, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyDepartment of Neurology, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyExperimental and Clinical Research Center, Max-Delbrück-Centrum für Molekulare Medizin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyNeuroscience Clinical Research Center, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyExperimental and Clinical Research Center, Max-Delbrück-Centrum für Molekulare Medizin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyNeuroscience Clinical Research Center, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyDepartment of Neurology, Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité – Universitätsmedizin Berlin, Berlin, GermanyThe first formal consensus diagnostic criteria for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) were recently proposed. Yet, the distinction of MOGAD-defining characteristics from characteristics of its important differential diagnoses such as multiple sclerosis (MS) and aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorder (NMOSD) is still obstructed. In preclinical research, MOG antibody-based animal models were used for decades to derive knowledge about MS. In clinical research, people with MOGAD have been combined into cohorts with other diagnoses. Thus, it remains unclear to which extent the generated knowledge is specifically applicable to MOGAD. Translational research can contribute to identifying MOGAD characteristic features by establishing imaging methods and outcome parameters on proven pathophysiological grounds. This article reviews suitable animal models for translational MOGAD research and the current state and prospect of translational imaging in MOGAD.https://www.frontiersin.org/articles/10.3389/fneur.2023.1216477/fullmyelin oligodendrocyte glycoprotein associated diseaseimagingtranslational researchEAEanimal models |
| spellingShingle | Frederike Cosima Oertel Frederike Cosima Oertel Frederike Cosima Oertel Maria Hastermann Maria Hastermann Friedemann Paul Friedemann Paul Friedemann Paul Delimiting MOGAD as a disease entity using translational imaging Frontiers in Neurology myelin oligodendrocyte glycoprotein associated disease imaging translational research EAE animal models |
| title | Delimiting MOGAD as a disease entity using translational imaging |
| title_full | Delimiting MOGAD as a disease entity using translational imaging |
| title_fullStr | Delimiting MOGAD as a disease entity using translational imaging |
| title_full_unstemmed | Delimiting MOGAD as a disease entity using translational imaging |
| title_short | Delimiting MOGAD as a disease entity using translational imaging |
| title_sort | delimiting mogad as a disease entity using translational imaging |
| topic | myelin oligodendrocyte glycoprotein associated disease imaging translational research EAE animal models |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2023.1216477/full |
| work_keys_str_mv | AT frederikecosimaoertel delimitingmogadasadiseaseentityusingtranslationalimaging AT frederikecosimaoertel delimitingmogadasadiseaseentityusingtranslationalimaging AT frederikecosimaoertel delimitingmogadasadiseaseentityusingtranslationalimaging AT mariahastermann delimitingmogadasadiseaseentityusingtranslationalimaging AT mariahastermann delimitingmogadasadiseaseentityusingtranslationalimaging AT friedemannpaul delimitingmogadasadiseaseentityusingtranslationalimaging AT friedemannpaul delimitingmogadasadiseaseentityusingtranslationalimaging AT friedemannpaul delimitingmogadasadiseaseentityusingtranslationalimaging |